Hormones and Reduction in Co-users of Marijuana and Nicotine

Marijuana Dependence Clinical Trial

Official title:

Sex Differences and Progesterone: Association With Impulsivity and Marijuana Reduction in Co-Users of Marijuana and Nicotine Cigarettes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02579421
• Other study ID #: 2015NTLS141
• Status: Completed
• Phase: N/A
• Start date: November 2015
• Est. completion date: July 27, 2017

Study information

• Verified date: June 2020
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to examine the role of progesterone (a naturally occurring hormone found in both men and women) on reducing marijuana use. The investigators will see if progesterone effects impulsivity, withdrawal, mood and stress during marijuana cessation.

Description:

This double-blind, randomized pilot clinical trial will prescreen an estimated 250 potential subjects, consent and further evaluate approximately 100 potential subjects, and ultimately enroll 70 subjects to ensure 40 subjects will provide a primary marijuana reduction outcome measure at four weeks post quit date. Subjects will be stratified by sex then randomized to one of two treatment groups (n=20 per drug group, 50% female): progesterone (PRO; 200mg 2x/day) or Placebo (PBO). Telephone screening and visit invitation (20 minutes) leads to the consent process and in-person screening including medical-psychiatric evaluation for inclusion/exclusion (two visits, two hours each), then randomization and medication start (7 days), then stable medication (28 days) with medication reduction and final evaluation (7 days).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: July 27, 2017
• Est. primary completion date: July 27, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Males 18-60 years old, females 18-50 years old

• Stable physical and mental health

• Self-report Timeline Follow-Back (TLFB) indicating current marijuana use =4 days/week for =1 year

• Positive urine THC dipstick test (> 50ng/mL; indicating marijuana use in the past 48-72 hours)

• Motivated to change their marijuana use (>1 on a 10-point Likert-type scale) -Regular or sporadic use of nicotine cigarettes (> 1 cigarettes in the past 30 days) -Self-report of regular menstrual cycles >6 months (female only)

• Willing to use double-barrier contraception if sexually active and not surgically sterilized (female only)

• Ability to comply with study procedures, ability to provide informed consent.

Exclusion Criteria:

• Current breastfeeding (females only),

• Current or planned pregnancy within the next three months (females only)

• DSM-IV diagnoses for psychotic disorders, bipolar disorder, ADHD, major depressive disorder within the last 3 months

• Substance dependence within the last 3 months with the exception of nicotine and marijuana dependence

• Unstable psychotropic medications (<3 months)

• Current use of exogenous hormones, finasteroid (propecia), efavirenz, red clover, ketoconazole and other drugs that are CYP3A4 inhibitors

• Conditions contraindicated to progesterone treatment (including, but not limited to, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke, allergy to peanuts, hypersensitive to progesterone and liver dysfunction)

Related Conditions & MeSH terms

• Marijuana Abuse
• Marijuana Dependence

Intervention

Drug:
• Progesterone
generic progesterone
• placebo
placebo

Locations

Country	Name	City	State
United States	Delaware Clinical Research Unit, University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Marijuana Use as Defined by the TLFB	Marijuana use as defined by the TLFB at the week 4 visit relative to the baseline visit.	5 weeks. Baseline to week 4